65,437 trials
Malignant Neoplasm · Nausea · Vomiting
Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Metastatic Bladder Urothelial Carcinoma · Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · Metastatic Ureter Urothelial Carcinoma
Primary: Progression-free Survival (PFS) — 8.0; 8.0 Months
Influenza, Human
Primary: Number of Participants Prescribed Antibiotics — 39; 32 Participants
Atopic Dermatitis
Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 14717 Number of Events
Chronic Gout
Primary: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time — 44; 40 Participants — p=0.181
Giant Cell Arteritis
Primary: Time to Flare by Week 26 — NA; 25.1 weeks — p=0.0263
Molybdenum Cofactor Deficiency, Type A
Primary: Safety of ORGN001 (Formerly ALXN1101) — 1; 5; 6; 2 events
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641 — 66.7; 64.9; 56.8; 65.5 nanograms per milliliter (ng/mL)
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019 — 7.6; 7.6; 5.5 Months — p=0.0001
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Metastatic Renal Cell Carcinoma
Primary: Efficacy of Pembrolizumab and Cabozantinib Based on Objective Response Rate — 65.8; 0 % of patients
Healthy Subject
Primary: Feasibility and Retention for a Trial With Daily Doses of 35 g of Fiber and 6.2 g of EPA +DHA (and Corresponding Comparators) — 14; 15; 1; 1 Participants
Small Cell Lung Cancer
Primary: Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) — 5; 25; 4; 9 Participants
Type 2 Diabetes
Primary: Change From Baseline in HbA1c in LY3502970 as Compared to Placebo — -1.19; -1.91; -1.79; -2.03 Percentage of HbA1c — p=<0.001